Sign up for Announcement alerts
January 2, 2015
Congratulations! Forty-eight (48) pharmacists were issued an Oklahoma Doctor of Pharmacy license during the period from November - December 2014 (click here to view).
November 4, 2014
E-PRESCRIBING OF CDS:
E-Prescribing of CII and CIII-V is permitted as long as the pharmacy and prescriber are EPCS (E-Prescribing of Controlled Substances) certified. A pharmacy whose software is EPCS certified will recognize other EPCS certified software and will accept CDS prescriptions from those prescribers who are also EPCS certified or reject those who are not.
Faxed prescriptions are not the same as electronic prescriptions. Faxed or written CDS prescriptions must bear the manual signature of the prescriber. They cannot bear a stamped, computer-generated signature, or “electronic signature on file”.
C-II prescriptions may not be faxed except under the exceptions allowed for hospice and LTCF patients. Please see OAC 475:30-1-4(f)(3) for complete rules.
November 4, 2014
Congratulations! One hundred forty-six (146) pharmacists were issued an Oklahoma Doctor of Pharmacy license during the period from August - October 2014 (click here to view).
October 2, 2014
NATIONAL TRANSPORTATION SAFETY BOARD (NTSB) ANNOUNCEMENT (click to view): On September 23, 2014, the NTSB issued a Safety Recommendation highlighting the importance of licensed health care providers and pharmacists routinely discussing with patients the effect their diagnosed medical conditions or recommended drugs may have on their ability to safely operate a vehicle in any mode of transportation.
August 28, 2014
NOTICE OF HYDROCODONE RESCHEDULE EFFECTIVE OCTOBER 6, 2014 (click to view): All products containing Hydrocodone will be rescheduled as a Schedule II (C-II) beginning October 6, 2014. To make the transition easier, the Board, working with multiple agencies, has summarized the essential information pertaining to the change. This summary is designed for the convenience of both pharmacists and practitioners and should be shared as necessary. Pharmacists should make an effort to share with all pharmacy staff.
August 5, 2014
TRAMADOL UPDATE: Tramadol will become a federally controlled Schedule IV beginning August 18, 2014. Though Tramadol has been a controlled substance in the State of Oklahoma since November 1, 2012, the DEA is requiring that pharmacies take an inventory of all Tramadol and Tramadol-containing products on AUGUST 18, 2014. The inventory must be kept on file in the pharmacy.
August 5, 2014
Congratulations! Eighty-six (86) pharmacists were issued an Oklahoma Doctor of Pharmacy license during the period from May - July 2014 (click here to view).
May 27, 2014
NOTICE OF PARENTERAL PERMIT & PHARMACIST-IN-CHARGE REQUIREMENTS FOR LICENSED NON-RESIDENT PHARMACIES (click to view Board memo)
Beginning July 1, 2014 there will be a change in the licensing requirements for non-resident pharmacies licensed by the Board that are compounding sterile drug products. If a licensed non-resident pharmacy is compounding sterile drug products, they must obtain an Oklahoma "Parenteral Permit" in addition to their pharmacy license.
Beginning January 1, 2015 all new and renewal non-resident pharmacy license applications that require a parenteral permit (i.e. pharmacies compounding sterile drug products) will also be required to have an Oklahoma license pharmacy manager or pharmacist-in-charge.
August 14, 2012
PSE questions & answers for pharmacies selling PSE. (click to view)
October 6, 2010
DEA Policy Statement on Role of Agents in Communicating CS Prescriptions:
Drug Enforcement Administration (DEA) issued a statement of policy that clarifies the proper role of a duly authorized agent of a DEA-registered individual practitioner in communicating controlled substance (CS) prescription information to a pharmacy. The statement, published October 6, 2010, in the Federal Register, reminds health care providers that a prescription for a CS medication must be issued by a DEA-registered practitioner acting in the usual course of professional practice. Such a practitioner may authorize an agent to “perform a limited role in communicating such prescriptions to a pharmacy in order to make the prescription process more efficient,” and the guidance emphasizes that medical determinations to prescribe CS medications may be made by the practitioner only. The specific circumstances in which an agent may assist in communicating prescription information to a pharmacy are detailed and include:
♦♦ An authorized agent may prepare the prescription, based on the instructions of the prescribing practitioner, for the signature of that DEA-registered practitioner.
♦♦ For a Schedule III-V drug, an authorized agent may transmit a practitioner-signed prescription to a pharmacy via facsimile, or may communicate the prescription orally to a pharmacy on behalf of the practitioner.
♦♦ An authorized agent may transmit by facsimile a practitioner signed Schedule II prescription for a patient in a hospice or long-term care facility (LTCF) on behalf of the practitioner.
The guidance also makes clear that generally, Schedule II prescriptions may not be transmitted by facsimile and that hospice and LTCFs are exceptions. Further,Schedule II prescriptions may only be communicated orally by the DEA-registered practitioner and only in emergency situations. DEA stresses that the practitioner should decide who may act as his or her authorized agent and advises that such designation be established in writing. An example written agreement is included in the policy statement, along with additional guidance related to designating an authorized agent. DEA also notes that as electronic prescribing for CS is implemented and its use increases, the role of the agent in communicating CS prescriptions will likely be reduced over time. The DEA policy statement is available on the Federal Register Web site at www.federalregister.gov/articles/2010/10/06/2010-25136/roleof-authorized-agents-in-communicating-controlled-substanceprescriptions-to-pharmacies.
July 2, 2009
EFFECTIVE IMMEDIATELY the following ID's are allowed in Oklahoma for PSE:
State Issued Driver's License
State Issued ID Card
If, and only if, a patient has none of these types of ID, such as a nursing home patient, then you may use a social security number to submit for PSE and PMP. For the purpose of accepting ID’s, please refer to the following definition: “State” means any state, territory, or possession of the United States, the District of Columbia, or foreign nation.
Any questions concerning PSE requirements should be directed to the Oklahoma Bureau of Narcotics at 405-521-2885.